Researchers at Rejuveron deploy knowledge gained in Nobel prize-winning...
Scientists working at Endogena, one of the companies in the Rejuveron family, are using their experience of a Nobel Prize-winning technique to create safe and effective therapies that promote healthy...
View ArticleRejuveron Transitions to Become a Clinical Stage Company as Rejuvenate Biomed...
Schlieren, Zürich, Switzerland · 29 March 2022 Rejuveron Life Sciences AG (‘Rejuveron’), a Zürich-based biotechnology company developing therapies to promote healthy aging, today announced that...
View ArticleClik here to view.
Rejuveron Age Better Live Longer Symposium
Join us to hear from leading economists, scientists, entrepreneurs and investors about the future direction of therapies to promote healthy aging. Register
View ArticleRejuveron CEO and Co-Founder Matthias Steger named as a 2022 In Vivo Rising...
Schlieren, Zürich, Switzerland · 19 April 2022 Rejuveron Life Sciences AG (‘Rejuveron’), a Zürich-based biotechnology company developing therapies to promote healthy aging, is delighted to announce...
View Article“My survival instinct sparked me to get into aging research”
Kevin Perrott, Ph.D., speaker at the Rejuveron Age better, live longer Symposium Kevin Perrott, Ph.D., is a successful entrepreneur and co-founder of the SENS Foundation. He used to run Canada’s...
View Article“Aging intersects with absolutely every other aspect of human experience”
Keith Comito, speaker at the Rejuveron Age better, live longer Symposium What sparked your interest to get into aging research? I would like to think that no matter life’s circumstances I would...
View ArticleGlobal Meetup in Zürich
Join us for our meetup Taking place in Zurich on June 23rd from 6 – 8pm at Café Auer & Co., Sihlquai 131. Explore the longevity ecosystem in Zurich and beyond. Community is key! Register
View ArticleSecond Rejuveron company transitions into clinical stage as first patient is...
Schlieren, Zürich, Switzerland · 12 July 2022 Rejuveron Life Sciences AG (‘Rejuveron’), a Zürich-based biotechnology company developing therapies to promote healthy aging, is pleased to announce...
View ArticleRejuveron raises $75 million in dual tranche Series B and convertible loan...
Rejuveron closes USD $75 million dual tranche Series B and convertible loan financing co-led by life science specialist Catalio Capital Management and Apeiron Investment Group. Mubadala Capital joins...
View ArticleRejuveron Life Sciences AG Rebrands as Centenara Labs AG and Provides Latest...
Shareholders approve name change and rebranding to Centenara Labs AG (“Centenara”) Rebrand positions business for strategic initiatives designed to support development of therapies for regenerative...
View Article